What role does ApoB play in menopause?

ApoB (Apolipoprotein B) is the primary structural protein of atherogenic lipoproteins (LDL, VLDL, IDL, Lp(a)) and a direct measure of particle number. During menopause, ApoB levels typically rise due to estrogen decline, which reduces LDL receptor activity and increases hepatic VLDL secretion. This increase contributes to the elevated cardiovascular risk seen in postmenopausal women. ApoB is considered a more accurate risk marker than LDL cholesterol because it captures the total number of atherogenic particles, including small dense LDL, which are particularly harmful. Evidence is human-strong (large epidemiological and clinical studies). Caveat: individual ApoB levels vary; lifestyle (diet, exercise) and hormone replacement therapy can modulate them. A DNA test (e.g., from MyBody-X) may identify genetic variants in lipid genes (APOE, CETP), but their effect is small. Blood-based ApoB measurement is clinically more relevant.